Using Pantoprazole to Protect Kidneys During Cancer Treatment
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
PHASE3 · Tanta University · NCT04217512
This study is testing if Pantoprazole can help protect the kidneys of patients with head and neck cancer from damage caused by the chemotherapy drug Cisplatin.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Sex | All |
| Sponsor | Tanta University (other) |
| Locations | 1 site (Tanta) |
| Trial ID | NCT04217512 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of Pantoprazole, a medication typically used to reduce stomach acid, to determine its protective effects against kidney damage caused by Cisplatin, a chemotherapy drug. The study involves administering Pantoprazole at low and high doses alongside standard hydration and Cisplatin to patients with head and neck cancer. The aim is to assess whether Pantoprazole can mitigate nephrotoxicity associated with Cisplatin treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with head and neck cancer.
Not a fit: Patients with a glomerular filtration rate (GFR) less than 59, diabetes mellitus, or significantly elevated liver enzymes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help protect patients' kidneys during chemotherapy, potentially improving their overall treatment outcomes.
How similar studies have performed: While the protective effects of Pantoprazole in this context are being explored, similar studies have not definitively established its efficacy, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with head and neck cancer Exclusion Criteria: * GFR less than 59. * DM * Elevated liver enzymes more than 3 fold.
Where this trial is running
Tanta
- Sherief Abd-Elsalam — Tanta, Egypt (RECRUITING)
Study contacts
- Principal investigator: Eman M Ghonaim, Msc — Demonstrator of Clinical Pharmacy
- Study coordinator: Sherief Abd-Elsalam, ass. prof.
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Oncology